IFNA2 and cancer: Paterson looked at 21 patients receiving high-dose interferon alpha-2b using the Functional Assessment of Cancer Therapy – Biological Response Modifier (FACT-BRM) scale, showing decreased QoL (Paterson et al, 2005).